Tekmira's Anti-Ebola Program to Proceed in Clinical Study With More Potent Formulation
13 déc. 2013 07h00 HE
|
Arbutus Biopharma Corporation
Supporting Studies Demonstrate Significant Increases in Potency
VANCOUVER, British Columbia, Dec. 13, 2013 (GLOBE NEWSWIRE) --Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading...
Tekmira Provides Corporate Update and Announces Third Quarter 2013 Results
13 nov. 2013 16h06 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira Announces New Preclinical Data from Anti-Viral Programs
12 nov. 2013 17h00 HE
|
Arbutus Biopharma Corporation
Results Demonstrate Survival Following Lethal Infection When Treatment Is Delayed
VANCOUVER, British Columbia, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR)...
Tekmira's Partner Initiates Phase III Trial With LNP-Enabled Patisiran (ALN-TTR02)
10 nov. 2013 23h28 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 10, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Tekmira Conference Call and Webcast Advisory: Corporate Update and Third Quarter Financial Results
07 nov. 2013 17h04 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Announces Closing of Underwriters' Full Over-Allotment Option
01 nov. 2013 11h12 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 1, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Preclinical Data Presented at Scientific Symposium Demonstrates That mRNA is Efficiently Delivered Using Tekmira's LNP
24 oct. 2013 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Announces Completion of US$30 Million Public Offering of Common Stock
22 oct. 2013 10h16 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira Prices Public Offering of Common Stock
17 oct. 2013 08h48 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 17, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira Announces Proposed Public Offering of Common Stock
16 oct. 2013 16h01 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 16, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...